Everpure, Inc., formerly known as Pure Storage, officially rebranded on February 23, 2026, to shift its market image and emphasize its innovative cloud storage solutions. The company focuses on the AI era's demand for a data-centric model, where data is a governed and shared system of record. Despite the rebranding, Everpure's stock is considered attractively valued relative to its growth potential, making it a favorable investment opportunity. The company remains a Buy recommendation for investors looking to capitalize on its technology and market position.
Everpure, Inc. is highlighted in this story about its growth potential. For readers following the Technology sector, here is Pluang's market snapshot as of Sep 18, 2026 21:31 WIB: Out of 150 priced Technology-sector US stocks tradable on Pluang, 36 rose and 113 fell today. Notable movers include SMCI at USD 38.67 with a 1-day change of -4.16% and a typical hold time on Pluang of 18 days, FIVN at USD 33.08 down 4.12% with 71 days typical hold time and 100% buy order activity, and ASAN at USD 9.68 down 4.06% with 34 days typical hold time and 100% buy order activity.
Grayscale Bitcoin Mini Trust (BTC) rose about 5.8% following Bitcoin's rebound above $80,000, reflecting renewed investor interest after the U.S. Senate failed to advance the CLARITY Act. The trust offers exposure to Bitcoin without direct ownership ...
Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...
Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...
Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...
VanEck introduced the VEEM ETF, which aims to outperform the MSCI Emerging Markets index by focusing on stocks with improving analyst sentiment rather than market cap weighting. This active strategy differs from traditional broad EM funds like VWO an...
